Recombinant Glucagon-like Peptide-1 (7-36 amide) Lowers Fasting Serum Glucose in a Broad Spectrum of Patients with Type 2 Diabetes

M. R. Ehlers; L. J. Klaff; D. A. D’Alessio; R. Brazg; H. D. Kay; R. E. Harley; A. L. Mathisen; R. Schneider

doi:10.1055/s-2003-43509

Hormone and Metabolic Research, Inhaltsverzeichnis

Horm Metab Res 2003; 35(10): 611-616
DOI: 10.1055/s-2003-43509

Original Clinical

Recombinant Glucagon-like Peptide-1 (7-36 amide) Lowers Fasting Serum Glucose in a Broad Spectrum of Patients with Type 2 Diabetes

M. R. Ehlers¹ , L. J. Klaff² , D. A. D’Alessio^3, ⁴ , R. Brazg² , H. D. Kay¹ , R. E. Harley¹ , A. L. Mathisen¹ , R. Schneider¹

¹Restoragen, Inc., Lincoln, Nebraska
²Rainier Clinical Research Center, Renton, Washington
³Department of Medicine, University of Washington, Seattle, Washington
⁴Department of Medicine, University of Cincinnati, Cincinnati, Ohio

Abstract

Aims: To evaluate the safety and efficacy of various doses of recombinant glucagon-like peptide-1 (7-36) amide (rGLP-1) administered subcutaneously (s. c.) via bolus injection or continuous infusion to lower fasting serum glucose (FSG) levels in subjects with type 2 diabetes treated by diet, hypoglycemic drugs, or insulin injection.

Methods: rGLP-1 was administered s. c. to 40 type 2 diabetics currently treated by diet, sulfonylurea (SU), metformin, or insulin in a double-blind, placebo-controlled, cross-over trial; preexisting treatments were continued during the study. In the bolus injection protocol, 32 subjects (8 from each of the 4 treatment groups) received 0.0, 0.5, 1.0, and 1.5 nmol rGLP-1/kg per injection (two injections, two hours apart, beginning one hour after the evening meal) in a randomized order on separate days. In the continuous s. c. infusion protocol, 40 subjects received rGLP-1 at 0.0, 1.5, 2.5, 3.5, and 4.5 pmol/kg/min for 10 - 12 hours overnight starting one hour after the evening meal. Fasting bloods were taken the morning after for glucose, insulin, and glucagon measurements.

Results: In the diet, SU, and metformin cohorts, bolus rGLP-1 injections produced modest reductions in mean FSG levels, averaging 17.4 mg/dl (7.3 - 27.5; 95 % CI) at the highest dose (p < 0.001 vs. placebo). Reductions in FSG levels were greater by continuous infusion at up to 30.3 mg/dl (18.8 - 41.8; 95 % CI; p < 0.001 vs. placebo). The greatest reduction in mean FSG occurred in the SU cohort (up to 43.9 mg/dl, 24.7 - 63.1; 95 % CI; p < 0.001). rGLP-1 infusions resulted in significant increases in fasting plasma insulin and decreases in fasting plasma glucagon levels. There were no serious adverse events; GI-related symptoms were dose-related and more commonly associated with injections.

Conclusions: rGLP-1 (7-36) amide dose-dependently lowered FSG in a broad spectrum of type 2 diabetics when added to their existing treatment. Subcutaneous infusion was more effective than injection, and the combination with SU was more effective than with metformin.

Key words

Incretin - GLP-1 - Continuous infusion - Sulfonylurea - Metformin

Volltext

Referenzen

References

1 King H, Aubert R E, Hdrman W H. Global burden of diabetes, 1995 - 2025. Diabetes Care. 1998; 21 1414-1431
2 Jovanovic L, Gondos B. Type 2 diabetes: the epidemic of the new millennium. Ann Clin Lab Sci. 1999; 29 33-42
3 DeFronzo R A. Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Reviews. 1997; 3 177-269
4 Weyer C, Tataranni P A, Bogardus C, Pratley R E. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care. 2000; 24 89-94
5 Kahn S E. The importance of β-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab. 2001; 86 4047-4058
6 Knudsen L B, Agerso H, Bjenning C, Bregenholt S, Carr R D, Godtfredsen C, Holst J J, Huusfeldt P O, Larsen M O, Larsen P J, Nielsen P F, Ribel U, Rolin B, Romer J, Sturis J, Wilken M, Kristensen P. GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes: selection of NN2211 for clinical development. Drugs Future. 2001; 26 677-685
7 Kieffer T J, Hussain M A, Habener J F. Glucagon and glucagon-like peptide production and degradation. In: Jefferson LS, Cherrington AD, Goodman HM (eds) Handbook of Physiology, section 7: The Endocrine Pancreas, vol. II: The Endocrine Pancreas and Regulation of Metabolism. Oxford; Oxford University Press 2001: 197-265
8 Habener J F. Glucagon-like peptide-1 agonist stimulation of β-cell growth and differentiation. Curr Opin Endocrinol Diab. 2001; 8 74-81
9 D’Alessio D A, Kahn S E, Leusner C R, Ensinck J W. Glucagon-like peptide 1 enhances tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest. 1994; 93 2263-2266
10 Meneilly G S, McIntosh C HS, Pederson R A, Habener J F, Gingerich R, Egan J M, Finegood D T, Elahi D. Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes. Diabetes Care. 2001; 24 1951-1956
11 Deacon C F, Nauck M A, Toft-Nielsen M, Pridal L, Willms B, Holst J J. Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH₂-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995; 44 1126-1131
12 Toft-Nielsen M, Madsbad S, Holst J J. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care. 1999; 22 1137-1143
13 Zander M, Madsbad S, Madsen J L, Holst J J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002; 359 824-830
14 Nauck M A, Wollschläger D, Werner J, Holst J J, Ørskov C, Creutzfeldt W, Willms B. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia. 1996; 39 1546-1553
15 Holst J J. Treatment of type 2 diabetes mellitus based on glucagon-like peptide-1. Exp Opin Invest Drugs. 1999; 8 1409-1415
16 Gutniak M K, Juntti-Berggren L, Hellström P M, Guenifi A, Holst J J, Efendic S. Glucagon-like peptide 1 enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas. Diabetes Care. 1996; 19 857-863
17 Ritzel R, Ørskov C, Holst J J, Nauck M A. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response relationships. Diabetologia. 1995; 38 720-725
18 Larsen J, Hylleberg B, Ng K, Damsbo P. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulfonylurea treatment. Diabetes Care. 2001; 24 1416-1421
19 Ørskov C, Poulsen S S, Moller M, Holst J J. Glucagon-like peptide 1 receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide 1. Diabetes. 1996; 45 832-835
20 Toft-Nielsen M, Madsbad S, Holst J J. Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycemia. Diabetologia. 1998; 41 1180-1186
21 Edwards C MB, Todd J F, Ghatei M A, Bloom S R. Subcutaneous glucagon-like peptide-1 (7-36) amide is insulinotropic and can cause hypoglycemia in fasted healthy subjects. Clin Science. 1998; 96 719-724

M. R. Ehlers, M. D., Ph. D.

Pacific Biometrics, Inc.

220 West Harrison Street · Seattle · WA 98119 · USA ·

eMail: marioe@pacbio.com

Fax: + 1 (206) 298 98 38